MAPP for Anxiety Disorders in Children (MAPP Trial)

N/A

Recruiting

Led By Golda S Ginsburg, PhD

Research Sponsored by UConn Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

6-17 years of age

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up youth will be assessed at 2 months (post intervention) and 6 months after eligibility is established.

Summary

This trial aims to help pediatric primary care providers help kids who are struggling with anxiety.

Who is the study for?

This trial is for children aged 6-17 who show signs of anxiety, with scores indicating mild to moderate symptoms. It's designed to help pediatricians better support these kids, especially where mental health resources are scarce.

What is being tested?

The MAPP clinical trial is testing a brief intervention called the Anxiety Action Plan (AxAP), aimed at reducing anxiety in children. Pediatric care providers will be trained and compared using AxAP versus Enhanced Usual Care involving educational materials.

What are the potential side effects?

Since this study involves non-medical interventions like training and educational materials, traditional physical side effects are not expected; however, there may be emotional or psychological responses unique to each child.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 6 and 17 years old.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ youth will be assessed at 2 months (post intervention) and 6 months after eligibility is established.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~youth will be assessed at 2 months (post intervention) and 6 months after eligibility is established.

This trial's timeline: 3 weeks for screening, Varies for treatment, and youth will be assessed at 2 months (post intervention) and 6 months after eligibility is established. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Clinical Global Impression Improvement scale

Primary Care Provider

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Managing Anxiety in Pediatric Primary Care (MAPP)Experimental Treatment1 Intervention

Participants receive approximately 4 sessions of a primary care provider-delivered intervention for reducing youth anxiety symptoms based on exposure therapy.

Group II: Enhanced Usual Care (EUC)Placebo Group1 Intervention

Participants receive a list of resources on how to reduce anxiety (e.g., videos, books, etc.).

0 / 1Eligibility criteria met